Biotech Values

[DewDiligence]

FDA approves NVS’ Tasigna in first-line CML:

http://finance.yahoo.com/news/FDA-Approves-Tasigna-for-prnews-1908800772.html?x=0&.v=1

Tasigna has worldwide annualized sales of $300M (#msg-49185209) based almost entirely on use in the second-line (Gleevec-refractory) setting. With the newly expanded label, Tasigna’s sales will increase greatly notwithstanding the fact that Tasigna will eventually have to split the first-line CML indication with GSK’s Sprycel and other agents. This can be ascertained from simple arithmetic: Gleevec, the NVS drug that Tasigna bested with ease in a head-to-head study (#msg-50898190), has annual sales of $4B (#msg-49185209).